Literature DB >> 22688424

HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells.

Fabian Wolpert1, Patrick Roth, Katrin Lamszus, Ghazaleh Tabatabai, Michael Weller, Günter Eisele.   

Abstract

Cancer stem cells are an attractive target for immunotherapeutic approaches to glioblastoma. However, an immune inhibitory phenotype of cells currently classified as "glioma-initiating cells" (GIC) might counteract recognition by immune effector cells. Here, we investigate the contribution of the non-classical MHC molecule HLA-E to the immunosuppressive phenotype of GIC. HLA-E is expressed in GIC lines and its expression is reduced upon differentiation of GIC in serum-containing culture conditions. Constitutive HLA-E inhibits natural killer (NK) cell-mediated lysis of GIC since small-interfering RNA-mediated HLA-E gene silencing enhances the immunogenicity of GIC. Increased GIC lysis was observed both in the CD133+ and in the CD133- compartment. Furthermore, the use of interferon-γ as a possible agent to boost an immune response against glioblastoma cells might be limited by the concurrent upregulation of HLA-E.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22688424     DOI: 10.1016/j.jneuroim.2012.05.010

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  21 in total

Review 1.  CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity.

Authors:  G Elizabeth Pluhar; Christopher A Pennell; Michael R Olin
Journal:  Crit Rev Immunol       Date:  2015       Impact factor: 2.214

Review 2.  Vaccine-based immunotherapeutic approaches to gliomas and beyond.

Authors:  Michael Weller; Patrick Roth; Matthias Preusser; Wolfgang Wick; David A Reardon; Michael Platten; John H Sampson
Journal:  Nat Rev Neurol       Date:  2017-05-12       Impact factor: 42.937

Review 3.  Strategies for isolating and enriching cancer stem cells: well begun is half done.

Authors:  Jiang-Jie Duan; Wen Qiu; Sen-Lin Xu; Bin Wang; Xian-Zong Ye; Yi-Fang Ping; Xia Zhang; Xiu-Wu Bian; Shi-Cang Yu
Journal:  Stem Cells Dev       Date:  2013-05-09       Impact factor: 3.272

Review 4.  Quo Vadis-Do Immunotherapies Have a Role in Glioblastoma?

Authors:  Sylvia C Kurz; Patrick Y Wen
Journal:  Curr Treat Options Neurol       Date:  2018-04-18       Impact factor: 3.598

5.  HLA-E and HLA-F Are Overexpressed in Glioblastoma and HLA-E Increased After Exposure to Ionizing Radiation.

Authors:  Tomas Hrbac; Alena Kopkova; Frantisek Siegl; Marek Vecera; Michaela Ruckova; Tomas Kazda; Radim Jancalek; Michal Hendrych; Marketa Hermanova; Vaclav Vybihal; Pavel Fadrus; Martin Smrcka; Filip Sokol; Vaclav Kubes; Radim Lipina; Ondrej Slaby; Leos Kren; Jiri Sana
Journal:  Cancer Genomics Proteomics       Date:  2022 Mar-Apr       Impact factor: 4.069

6.  A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells.

Authors:  Fabian Wolpert; Isabel Tritschler; Alexander Steinle; Michael Weller; Günter Eisele
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

7.  A critical role of non-classical MHC in tumor immune evasion in the amphibian Xenopus model.

Authors:  Nikesha Haynes-Gilmore; Maureen Banach; Eva-Stina Edholm; Edith Lord; Jacques Robert
Journal:  Carcinogenesis       Date:  2014-04-28       Impact factor: 4.944

8.  Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma.

Authors:  Jiangbing Zhou; Toral R Patel; Rachael W Sirianni; Garth Strohbehn; Ming-Qiang Zheng; Nha Duong; Thomas Schafbauer; Anita J Huttner; Yiyun Huang; Richard E Carson; Ying Zhang; David J Sullivan; Joseph M Piepmeier; W Mark Saltzman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-01       Impact factor: 11.205

9.  Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma.

Authors:  Manuela Silginer; Sara Nagy; Caroline Happold; Hannah Schneider; Michael Weller; Patrick Roth
Journal:  Neuro Oncol       Date:  2017-10-01       Impact factor: 12.300

Review 10.  Expression and function of immune ligand-receptor pairs in NK cells and cancer stem cells: therapeutic implications.

Authors:  Ioannis A Voutsadakis
Journal:  Cell Oncol (Dordr)       Date:  2018-02-22       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.